Jean‐Maurice Dumont

1.4k total citations
14 papers, 1.1k citations indexed

About

Jean‐Maurice Dumont is a scholar working on Molecular Biology, Virology and Hepatology. According to data from OpenAlex, Jean‐Maurice Dumont has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Virology and 6 papers in Hepatology. Recurrent topics in Jean‐Maurice Dumont's work include Signaling Pathways in Disease (8 papers), HIV Research and Treatment (6 papers) and Hepatitis C virus research (6 papers). Jean‐Maurice Dumont is often cited by papers focused on Signaling Pathways in Disease (8 papers), HIV Research and Treatment (6 papers) and Hepatitis C virus research (6 papers). Jean‐Maurice Dumont collaborates with scholars based in Switzerland, United States and Belgium. Jean‐Maurice Dumont's co-authors include Piétro Scalfaro, Johan Neyts, Brigitte Rosenwirth, Jan Paeshuyse, Grégoire Vuagniaux, Erik De Clercq, R. Crabbé, Ralf Bartenschlager, Artur Kaul and Urs T. Rüegg and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and Hepatology.

In The Last Decade

Jean‐Maurice Dumont

14 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Maurice Dumont Switzerland 13 588 481 383 198 176 14 1.1k
Toshitake Tanaka Japan 14 434 0.7× 892 1.9× 658 1.7× 135 0.7× 110 0.6× 30 1.5k
Nikolai Novikov United States 11 291 0.5× 231 0.5× 325 0.8× 282 1.4× 227 1.3× 19 821
C Bréchot France 14 275 0.5× 1.4k 2.9× 1.2k 3.2× 79 0.4× 70 0.4× 36 1.7k
Jens Kort United States 17 129 0.2× 905 1.9× 717 1.9× 407 2.1× 87 0.5× 61 1.4k
Grégory Camus United States 17 270 0.5× 455 0.9× 490 1.3× 312 1.6× 288 1.6× 32 1.1k
Shirish Paranjpe United States 19 254 0.4× 454 0.9× 284 0.7× 139 0.7× 95 0.5× 30 963
Xiumei Chi China 18 175 0.3× 512 1.1× 504 1.3× 80 0.4× 40 0.2× 53 917
Daisuke Akazawa Japan 16 210 0.4× 658 1.4× 522 1.4× 62 0.3× 83 0.5× 25 906
Michael Cooreman United States 13 254 0.4× 364 0.8× 417 1.1× 72 0.4× 26 0.1× 23 910
Kodjo Ayi Canada 19 270 0.5× 282 0.6× 278 0.7× 126 0.6× 68 0.4× 23 1.4k

Countries citing papers authored by Jean‐Maurice Dumont

Since Specialization
Citations

This map shows the geographic impact of Jean‐Maurice Dumont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Maurice Dumont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Maurice Dumont more than expected).

Fields of papers citing papers by Jean‐Maurice Dumont

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Maurice Dumont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Maurice Dumont. The network helps show where Jean‐Maurice Dumont may publish in the future.

Co-authorship network of co-authors of Jean‐Maurice Dumont

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Maurice Dumont. A scholar is included among the top collaborators of Jean‐Maurice Dumont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Maurice Dumont. Jean‐Maurice Dumont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Gallay, Philippe, Roger G. Ptak, Michael Bobardt, et al.. (2013). Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms. Viruses. 5(3). 981–997. 13 indexed citations
2.
Daelemans, Dirk, Jean‐Maurice Dumont, Brigitte Rosenwirth, Erik De Clercq, & Christophe Pannecouque. (2009). Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Research. 85(2). 418–421. 15 indexed citations
3.
Crabbé, R., et al.. (2008). An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opinion on Investigational Drugs. 18(2). 211–220. 33 indexed citations
4.
Flisiak, Robert, Andrzej Horban, Philippe Gallay, et al.. (2008). The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 47(3). 817–826. 179 indexed citations
5.
6.
Ptak, Roger G., Philippe Gallay, Dirk Jochmans, et al.. (2008). Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. Antimicrobial Agents and Chemotherapy. 52(4). 1302–1317. 93 indexed citations
7.
Inoue, Kazuaki, Takuya Umehara, Urs T. Rüegg, et al.. (2007). Evaluation of a cyclophilin inhibitor in hepatitis C virus–infected chimeric mice in vivo†. Hepatology. 45(4). 921–928. 73 indexed citations
8.
Gomez, Ludovic, Hélène Thibault, Jean‐Maurice Dumont, et al.. (2007). Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. American Journal of Physiology-Heart and Circulatory Physiology. 293(3). H1654–H1661. 144 indexed citations
9.
Flisiak, Robert, Jean‐Maurice Dumont, & R. Crabbé. (2007). Cyclophilin inhibitors in hepatitis C viral infection. Expert Opinion on Investigational Drugs. 16(9). 1345–1354. 38 indexed citations
10.
Paeshuyse, Jan, Artur Kaul, Erik De Clercq, et al.. (2006). The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro†. Hepatology. 43(4). 761–770. 223 indexed citations
11.
Chatterji, Udayan, Michael Bobardt, Robyn L. Stanfield, et al.. (2005). Naturally Occurring Capsid Substitutions Render HIV-1 Cyclophilin A Independent in Human Cells and TRIM-cyclophilin-resistant in Owl Monkey Cells. Journal of Biological Chemistry. 280(48). 40293–40300. 64 indexed citations
12.
Hansson, Magnus J., Gustav Mattiasson, Roland Månsson, et al.. (2004). The Nonimmunosuppressive Cyclosporin Analogs NIM811 and UNIL025 Display Nanomolar Potencies on Permeability Transition in Brain-Derived Mitochondria. Journal of Bioenergetics and Biomembranes. 36(4). 407–413. 113 indexed citations
13.
Hildebrand, Pius, Gayathri Nair, Sylvia Ketterer, et al.. (2000). Vapreotide, a long-acting somatostatin analogue, dose-dependently inhibits exocrine pancreatic secretion in healthy volunteers. Gastroenterology. 118(4). A415–A415. 2 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshitake Tanaka Breakdown of academic impact, for papers by Nikolai Novikov Breakdown of academic impact, for papers by C Bréchot Breakdown of academic impact, for papers by Jens Kort Breakdown of academic impact, for papers by Grégory Camus Breakdown of academic impact, for papers by Shirish Paranjpe Breakdown of academic impact, for papers by Xiumei Chi Breakdown of academic impact, for papers by Daisuke Akazawa Breakdown of academic impact, for papers by Michael Cooreman Breakdown of academic impact, for papers by Kodjo Ayi
Rankless by CCL
2026